2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

1997 Characterization of atypical breakpoints of BCR::ABL1 rearrangements in chronic myelogenous leukemia (CML) and other myeloid malignancies

Ehab Atallah, MD, Alyssa Kruger2, Justin Allen3, Richard SP Huang, MD4, Lincoln Wain Pasquina, PhD5, Natalie Danziger6
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Foundation Medicine, Inc., Boston, Massachusetts, United States
3 Foundation Medicine, Inc., Boston, Massachusetts, United States
4 Foundation Medicine, Inc., Boston, Massachusetts, United States
5 Foundation Medicine, Inc., Boston, Massachusetts, United States
6 Foundation Medicine, Inc., Boston, Massachusetts, United States

Introduction

The BCR::ABL1 rearrangement is found in acute lymphoblastic leukemia (ALL) and CML (chronic myeloid leukemia), among other hematologic diseases. Both BCR and ABL1 exhibit a variety of rearrangement breakpoints. CML typically harbors BCR exon 13/14::ABL1 exon 2 (e13/14a2), resulting in the p210 protein, while ALL typically contains e1a2 (p190). In addition, alternative breakpoints (not e1/13/14a2) are found across diseases, with increased clinical importance since the advent of the latest targeted therapies. In particular, understanding whether the SH3 domain of ABL1, with its protein coding sequence beginning mid-way in exon 2, is intact is needed to inform use of ABL1-targeting tyrosine kinase inhibitors (TKI) that bind to that region, the so-called STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitors. Further, alterations within the ABL1 kinase domain and other genes have an increasing relevance for TKI use and sequencing. Here we characterize BCR::ABL1 rearrangements by breakpoint using a broad DNA- and RNA-based next generation sequencing (NGS) assay across hematologic malignancies, and evaluate co-occurring alterations in a subset of patients with CML.

 

Methods

We queried 11,767 samples from patients with acute leukemias or myeloproliferative neoplasms (MPNs) for rearrangements of BCR::ABL1 detected on FoundationOne®Heme, a laboratory developed test that assesses 406 genes by DNA and 265 by RNA using NGS. Samples were submitted for testing during the course of clinical care with diagnoses determined by the ordering physician.

 

Results

We identified 728 specimens with BCR::ABL1. Diagnosis submitted at time of sequencing was CML for 241 (33.1%) pts, ALL for 330 (45.2%; 288 [87%] age >=18), and other myeloid malignancies (acute leukemia NOS, AML, MDS-MPN, MPN NOS) for 157 (21.6%). Among pts with CML, 217 (90.0%) of BCR::ABL1 corresponded to e13a2 or e14a2 transcripts and 6 (2.5%) corresponded to e1a2 transcripts. Among ALL, 236 (71.5%) were BCR::ABL1 e1a2 and 77 (23.3%) were e13/14a2.

Atypical breakpoints were found in 41 (5.6%) BCR::ABL1+ cases, including 18 (7.5%) in CML and 17 (5.2%) in ALL. These included breakpoints within exon 2 of ABL1 but still upstream of the bases expected to code for the SH3 domain paired with various breakpoints within BCR (within exons 1 and 12 and introns 1, 4,  12, and 13) (n=26, 63.4%). 13/41 (31.7%) cases had breakpoints anticipated to result in the exclusion of exon 2 of ABL1 and therefore predicted to lack expression of the ABL1 SH3 domain. These included breakpoints in intron 2 (n=10) and intron 3 (n=3), yielding the following expected transcripts: e1a3, e12a3, e13a3, e14a3, e1a4, and e12a4. 2 cases had atypical breakpoints of BCR but canonical breakpoints of ABL1 (e2a2 and e12a2). 

Resistance alterations in ABL1 kinase domain were found in 37/241 (15.3%) CML cases. The most common were T315I (n=18), F317X (n=4) and E255X (n=3). 8/37 (XX%) patients harbored more than one ABL1 kinase domain mutation. The most common co-occurring gene alterations among all 241 patients with BCR::ABL1-positive CML were in ASXL1 (22.8%), RUNX1 (5.0%), DNMT3A (4.1%), and TET2 (4.1%). ASXL1 alterations were numerically but not statistically more frequent in CML samples with typical BCR::ABL1 breakpoints than those with atypical BCR::ABL1 breakpoints (23.8% vs 11.1%, p=0.4).

 

Conclusion

BCR::ABL1 rearrangements were observed in a variety of myeloid malignancies but enriched in CML and ALL as expected. The detection of atypical breakpoints of BCR::ABL1 rearrangements in 6% of cases highlights the unique information that can be derived from a broad DNA and RNA  NGS-based test, with implications for treatment decisions given how the intactness of the SH3 domain of ABL1 can impact the effectiveness of some novel ABL1-targeting tyrosine kinase inhibitors.

Ehab Atallah, MD: Strong and Hanni - Honoraria; BMS - Honoraria; AbbVie - Honoraria; Syndax - Honoraria; Novartis - Research Funding; Xencor - Research Funding; Amgen - Research Funding; UpToDate - Patents & Royalties; Strong and Hanni - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Inhibikinase - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)